Imunon, Inc.

Equities

IMNN

US15117N6022

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 04:00:00 2025-01-17 pm EST			5-day change	1st Jan Change
0.9131 ^USD	+1.68%		+1.47%	-3.88%

Dec. 19	IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	CI
Dec. 10	Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	CI

Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024

August 14, 2024 at 08:00 am EDT

Imunon, Inc. reported earnings results for the second quarter and six months ended June 30, 2024. For the second quarter, the company reported net loss was USD 4.79 million compared to USD 5.56 million a year ago. Net loss was USD 4.79 million compared to USD 5.56 million a year ago. Net loss was USD 4.79 million compared to USD 5.56 million a year ago. Net loss was USD 4.79 million compared to USD 5.56 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.61 a year ago.
For the six months, net loss was USD 9.72 million compared to USD 11.15 million a year ago. Net loss was USD 9.72 million compared to USD 11.15 million a year ago. Net loss was USD 9.72 million compared to USD 11.15 million a year ago. Net loss was USD 9.72 million compared to USD 11.15 million a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 1.28 a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 1.28 a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 1.28 a year ago. Basic loss per share from continuing operations was USD 1.03 compared to USD 1.28 a year ago.

Latest news about Imunon, Inc.

IMUNON, Inc. Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer	Dec. 19	CI
Imunon Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 Ovation 2 Study of Imnn-001	Dec. 10	CI
Imunon, Inc. Announces Results from its End-Of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer	Nov. 25	CI
Imunon, Inc., Q3 2024 Earnings Call, Nov 07, 2024	Nov. 07
IMUNON, Inc. Announces the Presentation of New Clinical Data from the Recently Completed Phase 2 Study of IMNN-001	Nov. 07	CI
Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	Nov. 07	CI
IMUNON, Inc. to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting	24-10-30	CI
Imunon, Inc. Appoints Susan Eylward as General Counsel and Corporate Secretary	24-10-07	CI
Imunon Files for Stock Resale by Security Holders	24-08-29	MT
Imunon, Inc. announced that it has received $10 million in funding	24-08-15	CI
Imunon, Inc., Q2 2024 Earnings Call, Aug 14, 2024	24-08-14
Imunon, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-08-14	CI
Imunon, Inc. announced that it expects to receive $10 million in funding	24-07-31	CI
Sector Update: Health Care Stocks Softer in Late Afternoon Trading	24-07-31	MT
Sector Update: Health Care	24-07-31	MT
Top Midday Decliners	24-07-31	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	24-07-30	MT
Sector Update: Health Care	24-07-30	MT
Top Midday Gainers	24-07-30	MT
Imunon Shares More Than Double on Ovarian Cancer Study Results	24-07-30	DJ
Imunon Says Phase 2 Trial Data of Ovarian Cancer Treatment Showed Increase in Overall Survival; Shares Jump	24-07-30	MT
Imunon, Inc. - Special Call	24-07-30
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001	24-07-30	CI
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer	24-06-24	CI
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial	24-06-05	CI

Chart Imunon, Inc.

Duration

Period

IMNN: Dynamic Chart

Company Profile

Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

2025-03-26 - Q4 2024 Earnings Release (Projected)

More about the company